全文获取类型
收费全文 | 180篇 |
免费 | 8篇 |
专业分类
妇产科学 | 2篇 |
基础医学 | 17篇 |
临床医学 | 17篇 |
内科学 | 28篇 |
皮肤病学 | 1篇 |
神经病学 | 13篇 |
特种医学 | 5篇 |
外科学 | 69篇 |
预防医学 | 12篇 |
眼科学 | 1篇 |
药学 | 11篇 |
中国医学 | 5篇 |
肿瘤学 | 7篇 |
出版年
2021年 | 4篇 |
2018年 | 4篇 |
2016年 | 4篇 |
2015年 | 7篇 |
2014年 | 4篇 |
2013年 | 4篇 |
2012年 | 14篇 |
2011年 | 13篇 |
2010年 | 6篇 |
2009年 | 4篇 |
2008年 | 8篇 |
2007年 | 16篇 |
2006年 | 10篇 |
2005年 | 5篇 |
2004年 | 2篇 |
2003年 | 9篇 |
2002年 | 7篇 |
2001年 | 4篇 |
2000年 | 3篇 |
1999年 | 4篇 |
1996年 | 1篇 |
1995年 | 1篇 |
1994年 | 1篇 |
1993年 | 3篇 |
1992年 | 2篇 |
1991年 | 2篇 |
1990年 | 1篇 |
1989年 | 4篇 |
1987年 | 3篇 |
1986年 | 1篇 |
1985年 | 3篇 |
1984年 | 3篇 |
1983年 | 2篇 |
1982年 | 1篇 |
1981年 | 2篇 |
1980年 | 1篇 |
1979年 | 2篇 |
1978年 | 3篇 |
1977年 | 2篇 |
1976年 | 3篇 |
1975年 | 3篇 |
1974年 | 2篇 |
1972年 | 1篇 |
1970年 | 1篇 |
1967年 | 1篇 |
1947年 | 1篇 |
1941年 | 1篇 |
1939年 | 1篇 |
1932年 | 1篇 |
1925年 | 1篇 |
排序方式: 共有188条查询结果,搜索用时 15 毫秒
1.
The effect of delayed graft function and immunosuppressive drugs on posttransplant erythropoiesis was studied prospectively in 18 living-related (LR) and 84 cadaver-donor (CD) recipients. Eight of 18 LR and 20 of 84 CD recipients received antilymphoblast globulin (ALG) in addition to azathioprine and prednisone. Sixty-four CD recipients received cyclosporine (CsA) with prednisone. In the absence of rejection reticulocytosis began 6.7 +/- 0.2 days following graft implantation in azathioprine-only-treated LR recipients. This was lengthened by ALG to 9.4 +/- 0.3 and 9.9 +/- 0.7 days in LR and CD recipients, respectively, whose grafts functioned immediately. Delayed graft function prolonged onset of reticulocytosis to 15.9 +/- 0.9 days in ALG-treated but not in CsA-treated recipients (5.8 +/- 0.4 days). The shortest latency was noted in CsA-treated recipients (4.9 +/- 0.5 days) with immediately functioning grafts. The earlier onset of reticulocytosis of CsA-treated recipients was followed by statistically significant blunting of peak reticulocytosis, which correlated with a slower rate of correction of anemia (delta Hct = 0.19/day) compared with non-CsA-treated recipients (delta Hct = 0.34/day). Early rejection was associated with abrogation of reticulocytosis and correction of anemia without regard to immunosuppressive regimen) until rejection was reversed. Erythropoietin (EPO) was measured sequentially in 5 patients with immediate function. In 4 of 5 cases changes in EPO preceded those in reticulocytosis. EPO rose from a mean of 13 mU/ml pretransplant to a peak of 50 within 3 weeks and decreased to 18 mU/ml within 6 weeks of graft implantation. At six months posttransplant, normalized reticulocyte counts were only 55% higher (1.75 vs. 1.13%) but hematocrit had increased from 26 +/- 1% to 42 +/- 1%. Hematocrit varied inversely with serum creatinine, which was highest in CsA-treated patients with initial delayed graft function. We conclude that correction of anemia posttransplantation is driven by EPO but other factors may also be important, that neither ATN nor ALG-therapy have clinically important effects on erythropoiesis, and that CsA reduced "effective" erythropoiesis and influences correction of anemia--particularly if delayed graft function complicates the initial course posttransplantation. 相似文献
2.
Fokam Tagne Michel Archange Tchoffo Anatole Noubissi Paul Aimé Mazo Aimée Gisolène Kom Blaise Ngakou Mukam Joseph Sokeng Dongmo Sélestin Kamgang René 《Inflammopharmacology》2021,29(4):1211-1223
Inflammopharmacology - Ulcerative colitis is a form of inflammatory bowel disease that is characterized by acute and chronic inflammation. The aim of this work was to evaluate the efficacy of... 相似文献
3.
4.
5.
RA Distasio OA von Lilienfeld A Tkatchenko 《Proceedings of the National Academy of Sciences of the United States of America》2012,109(37):14791-14795
Van der Waals (vdW) interactions are ubiquitous in molecules and condensed matter, and play a crucial role in determining the structure, stability, and function for a wide variety of systems. The accurate prediction of these interactions from first principles is a substantial challenge because they are inherently quantum mechanical phenomena that arise from correlations between many electrons within a given molecular system. We introduce an efficient method that accurately describes the nonadditive many-body vdW energy contributions arising from interactions that cannot be modeled by an effective pairwise approach, and demonstrate that such contributions can significantly exceed the energy of thermal fluctuations-a critical accuracy threshold highly coveted during molecular simulations-in the prediction of several relevant properties. Cases studied include the binding affinity of ellipticine, a DNA-intercalating anticancer agent, the relative energetics between the A- and B-conformations of DNA, and the thermodynamic stability among competing paracetamol molecular crystal polymorphs. Our findings suggest that inclusion of the many-body vdW energy is essential for achieving chemical accuracy and therefore must be accounted for in molecular simulations. 相似文献
6.
A Besarab SN Zeig ER Martin PE Pergola FC Whittier RI Zabaneh B Schiller M Mayo CA Francisco KR Polu AM Duliege 《BMC nephrology》2012,13(1):95
ABSTRACT: BACKGROUND: Peginesatide is a peptide-based erythropoiesis-stimulating agent that was designed and engineered to stimulate specifically the erythropoietin receptor dimer that governs erythropoiesis. The primary objective of this phase 2 dose-finding study was to determine the once-monthly peginesatide dosing strategy that would maintain hemoglobin within [PLUS-MINUS SIGN]1.0 g/dL of baseline values after conversion from epoetin alfa; the safety of peginesatide was evaluated concurrently. METHODS: Chronic hemodialysis patients on stable regimens of epoetin alfa were sequentially assigned to cohorts that differed on (1) how the peginesatide starting dose was determined (using a single epoetin alfa--to-peginesatide dose conversion ratio or a tiered, weight-based or absolute-dose conversion table) and on (2) whether or not a 1-week erythropoiesis-stimulating agent-free interval was used. Peginesatide doses were titrated to maintain hemoglobin levels within [PLUS-MINUS SIGN]1.0 g/dL from baseline. RESULTS: A total of 164 patients were enrolled and received intravenous peginesatide every 4 weeks for up to 6 doses; the duration of the study including follow-up was [LESS-THAN OR EQUAL TO]29 weeks. Overall, the proportion of patients with hemoglobin levels within [PLUS-MINUS SIGN]1.0 g/dL of baseline increased over the course of the study from 39% (Weeks 2--13) to 54% (Weeks 18--25). Cohorts that used tiered dose conversion tables trended towards having more stable peginesatide doses than did those cohorts that used a single dose conversion ratio. Moreover, cohorts that used an erythropoiesis-stimulating agent-free interval did not have the substantial initial increase in hemoglobin levels that was seen in those cohorts that did not use such an interval. In this study, the safety profile of peginesatide was consistent with those of marketed erythropoiesis-stimulating agents. CONCLUSIONS: The results of this study were used to guide the dosing regimens used subsequently in phase 3 studies. Once-monthly peginesatide is feasible in hemodialysis patients.Trial registrationClinicalTrials.gov registration: NCT00228449. 相似文献
7.
Ryan D. Kilpatrick Cathy W. Critchlow Steven Fishbane Anatole Besarab Catherine Stehman-Breen Mahesh Krishnan Brian D. Bradbury 《Clinical journal of the American Society of Nephrology》2008,3(4):1077-1083
Background and objectives: Among hemodialysis patients, achieved hemoglobin is associated with Epoetin alfa dose and erythropoietin responsiveness. A prospective erythropoietin responsiveness measure was developed and its association with mortality evaluated.Design, setting, participants, & measurements: Data from 321 participants were used and randomized to the hematocrit normalization arm of the Normal Hematocrit Cardiac Trial. Subjects were to receive a 50% Epoetin alfa dose increase at randomization. The prospective erythropoietin responsiveness measure was defined as the ratio of weekly hematocrit change (over the 3 wk after randomization) per Epoetin alfa dose increase (1000 IU/wk) corresponding to the mandated 50% dose increase at randomization. The distribution of responsiveness was divided into quartiles. Over a 1-yr follow-up, Cox proportional hazard modeling evaluated associations between this responsiveness measure and mortality.Results: Erythropoietin responsiveness values ranged from −2.1% to 2.4% per week per 1000 IU. Although subjects were similar across response quartiles, mortality ranged between 14% and 34% among subjects in the highest and lowest response quartiles (P = 0.0004), respectively. After adjusting for baseline prognostic indicators, highest versus lowest responsiveness was associated with a hazard ratio of 0.41 (95% confidence interval, 0.20 to 0.87).Conclusion: Lower erythropoietin responsiveness is a strong, independent predictor of mortality risk and should be considered when evaluating associations between clinical outcomes and potential prognostic indicators, such as Epoetin alfa dose and achieved hemoglobin values.More than 90% of end-stage renal disease patients require exogenous erythropoietin or transfusion to achieve and maintain target hemoglobin values (1,2) because of decreased endogenous erythropoietin production. The ability to achieve and maintain target hemoglobin levels is complicated by a variety of mediating factors that impact responsiveness to erythropoietin, including comorbidities, inflammation, and malnutrition. These factors are independently associated with poor clinical outcomes (3–9).The impact of erythropoietin responsiveness on mortality is not well understood. Although higher hemoglobin levels have been associated with reduction in mortality in observational studies (10,11), evidence from randomized clinical trials of hemodialysis patients does not suggest a mortality benefit (12). Paradoxically, in the Normal Hematocrit Cardiac Trial (13), the largest randomized trial conducted to date in hemodialysis patients, survival rates were higher among those achieving higher hematocrit values, but targeting a higher hematocrit was associated with a 1.3-fold increased risk of mortality or nonfatal myocardial infarction (95% confidence interval [CI], 0.9 to 1.9). This suggests that unknown/unmeasured patient characteristics associated with the ability to achieve greater hemoglobin values may confound analyses assessing mortality risks among dialysis patients.Achieved hemoglobin level is associated with both the Epoetin alfa doses administered and patient responsiveness to erythropoietin. Greater survival among patients with higher hemoglobin values may be partly due to greater erythropoietin responsiveness (14) in addition to a direct result of anemia correction. Likewise, lower survival among those with lower achieved hemoglobin values may be partly the result of lower relative erythropoietin responsiveness. Patients who require higher Epoetin alfa doses to achieve a given hemoglobin level, that is, who are less responsive to erythropoietin, may experience poorer outcomes at any achieved hemoglobin value (15).In this study, data from the hematocrit normalization arm of the Normal Hematocrit Cardiac Trial (13) were used to develop a prospective measure of erythropoietin responsiveness, which was then evaluated in relation to mortality. 相似文献
8.
9.
The isolated rat kidney perfused at 37 C was used to evaluate the effect of adding plasma proteins to, and varying osmolality of, cold-storage flushing solutions with or without buffering. Addition of albumin improved immediate poststorage kidney function (glomerular filtration rate [GFR], fractional sodium reabsorption, and fractional protein clearance) of all flushing solutions tested after 6 hr and 24 hr of storage. At 6 hr, these improvements also correlated with less weight gain. Flushing solutions containing citrate and sulfate produced significantly better return of function after 24 hr of cold storage than Krebs' or Collins'-derived solutions. Osmolality was unimportant with solutions containing citrate. Collins' solution with reduced MgSO4 yielded better poststorage function than conventional solution. An all-citrate isotonic solution buffered with 15 mmol THAM preserved poststorage function at 48 hr better than a similarly buffered solution containing both citrate and sulfate. Loss of dry weight during storage and subsequent perfusion appeared to correlate, in these experiments, with loss of poststorage function. The isolated rat kidney provides discrimination among various flushing solutions. The technique might be useful in the assay of additional variables that might affect the quality of kidney preservation. 相似文献
10.